Use of radiolabeled antibodies in the treatment of childhood acute leukemia

Eneida Nemecek, Dana C. Matthews

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalPediatric Transplantation
Volume7
Issue numberSUPPL. 3
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Leukemia
Recurrence
Antibodies
Hematopoietic Stem Cells
Treatment Failure
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Radiation
Transplants
Antigens
Therapeutics

Keywords

  • Acute leukemia
  • Anti-CD45 antibody
  • Radiolabeled antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Use of radiolabeled antibodies in the treatment of childhood acute leukemia. / Nemecek, Eneida; Matthews, Dana C.

In: Pediatric Transplantation, Vol. 7, No. SUPPL. 3, 2003, p. 89-94.

Research output: Contribution to journalArticle

@article{4b4612a960784d0ca13fe9d59f60bc82,
title = "Use of radiolabeled antibodies in the treatment of childhood acute leukemia",
abstract = "Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.",
keywords = "Acute leukemia, Anti-CD45 antibody, Radiolabeled antibodies",
author = "Eneida Nemecek and Matthews, {Dana C.}",
year = "2003",
doi = "10.1034/j.1399-3046.7.s3.14.x",
language = "English (US)",
volume = "7",
pages = "89--94",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Use of radiolabeled antibodies in the treatment of childhood acute leukemia

AU - Nemecek, Eneida

AU - Matthews, Dana C.

PY - 2003

Y1 - 2003

N2 - Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.

AB - Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.

KW - Acute leukemia

KW - Anti-CD45 antibody

KW - Radiolabeled antibodies

UR - http://www.scopus.com/inward/record.url?scp=0037219279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037219279&partnerID=8YFLogxK

U2 - 10.1034/j.1399-3046.7.s3.14.x

DO - 10.1034/j.1399-3046.7.s3.14.x

M3 - Article

C2 - 12603700

AN - SCOPUS:0037219279

VL - 7

SP - 89

EP - 94

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - SUPPL. 3

ER -